Literature DB >> 9450858

Is hereditary site-specific ovarian cancer a distinct genetic condition?

A Liede1, P N Tonin, C C Sun, C Serruya, M B Daly, S A Narod, W D Foulkes.   

Abstract

It is not clear if hereditary site-specific ovarian cancer exists as a genetic entity distinct from the hereditary breast-ovarian cancer syndrome. We have identified a large Ashkenazi Jewish kindred with 8 cases of ovarian carcinoma and no cases of breast cancer. Initially, linkage analysis for this kindred generated a negative LOD score to BRCA1, but subsequent mutation and haplotype analysis of key individuals demonstrated a BRCA1 185delAG mutation segregating with all but 1 of the ovarian cancer cases. This observation has important implications for genetic counselling of families with site-specific ovarian cancer. Hereditary site-specific ovarian cancer is likely to be a variant of the hereditary breast-ovarian cancer syndrome, attributable to either BRCA1 or BRCA2. We consider women from these families to be at increased risk of breast cancer and counsel them accordingly.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9450858     DOI: 10.1002/(sici)1096-8628(19980106)75:1<55::aid-ajmg12>3.0.co;2-r

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  4 in total

Review 1.  Forth nightly review: hereditary ovarian carcinoma.

Authors:  L Kasprzak; W D Foulkes; A N Shelling
Journal:  BMJ       Date:  1999-03-20

2.  Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.

Authors:  A Dørum; K Heimdal; E Hovig; M Inganäs; P Møller
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 3.  Familial ovarian cancer.

Authors:  L Elit
Journal:  Can Fam Physician       Date:  2001-04       Impact factor: 3.275

4.  A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.

Authors:  Patricia N Tonin; Christine M Maugard; Chantal Perret; Anne-Marie Mes-Masson; Diane M Provencher
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.